David Kabakoff, Ph.D., Chairman,
is a well known and respected life sciences executive and adviser, now operating Strategy Advisers to provide business and strategic advisory services to life sciences companies and investors. Prior to its acquisition by Cephalon, Inc., in June 2005, Dr. Kabakoff served as Chairman and Chief Executive Officer of Salmedix, Inc., a company he co-founded to develop novel oncology drugs. Previously, Dr. Kabakoff held executive management positions with Dura Pharmaceuticals, a specialty pharmaceutical company that was acquired by Elan Pharmaceuticals. Prior to joining Dura, Dr. Kabakoff was Chairman and Chief Executive Officer of Corvas International, a biopharmaceutical firm focused on cardiovascular and inflammatory diseases. He has also held senior management positions with Hybritech, Inc., a pioneer in the field of monoclonal antibodies, which was acquired by Eli Lilly & Co. Dr. Kabakoff received his Ph.D. in Chemistry from Yale University and his B.A. in Chemistry from Case Western Reserve University.